Preexisting T-cell immunity directed at conserved viral regions promotes enhanced recovery from influenza virus infections, with there being some evidence of cross-protection directed at variable peptides. Strikingly, many of the immunogenic peptides derived from the current pandemic A(H1N1)-2009 influenza virus are representative of the catastrophic 1918 "Spanish flu" rather than more recent "seasonal" strains. We present immunological and structural analyses of cross-reactive CD8 + T-cell-mediated immunity directed at a variable (although highly cross-reactive) immunodominant NP [418] [419] [420] [421] [422] [423] [424] [425] [426] peptide that binds to a large B7 family (HLA-B*3501/03/0702) found throughout human populations. Memory CD8 + T-cell specificity was probed for 12 different NP 418 mutants that emerged over the 9 decades between the 1918 and 2009 pandemics. Although there is evidence of substantial cross-reactivity among seasonal NP 418 418 epitopes. This analysis points to the potential importance of cross-reactive T-cell populations that cover the possible spectrum of T-cell variants and suggests that the identification of key residues/motifs that elicit cross-reactive T-cell sets could facilitate the evolution of immunization protocols that provide a measure of protection against unpredicted pandemic influenza viruses. Thus, it is worth exploring the potential of vaccines that incorporate peptide variants with a proven potential for broader immunogenicity, especially to those that are not recognized by the current memory T-cell pool generated by exposure to influenza variants that cause successive seasonal epidemics.
influenza infection | T-cell responses | B7 allelic family | NP418-426 variants T he rapid global spread of the A(H1N1)-2009 "swine origin" influenza virus in human populations led the World Health Organization (WHO) to declare this the first influenza pandemic of the 21st century (1). Although A(H1N1)-2009 has not caused uniformly severe disease, the perception that the 1918-1919 H1N1 catastrophe (>40 million people died) began with an earlier milder phase raises the specter that this newly emerged virus could mutate to increased virulence. As it is, women in the third trimester of pregnancy, the very obese, and those living in communities with poor basic health and nutrition seem to be at increased risk, and there have been fatal cases in otherwise healthy children. The A(H1N1)-2009 statistics are also skewed by the fact that although influenza is normally most severe in the elderly, those who were alive before 1950 have some level of preexisting immunity (2) .
In the absence of cross-reactive neutralizing antibodies, one way of minimizing the severity of influenza A virus infections is to recall established T-cell memory directed at peptides derived from relatively invariant internal proteins. Evidence from animal models (3) and humans (4-6) indeed suggests a role for CD8 + T-cellmediated protection following heterologous prime/challenge between H1N1, H7N7, H3N2, and H5N1 viruses. Such cross-reactive CD8 + T-cell-mediated immunity has, in the face of an emerging influenza pandemic, the potential to ameliorate the disease by promoting enhanced recovery.
Protective CD8 + T-cell-mediated immunity can be directed at peptides that are, like M1 58 (7) , conserved among different influenza subtypes and strains or vary at non-MHC anchor residues in a way that still allows productive T-cell receptor (TCR) binding (8, 9) . Thus, although only ∼50% (10) of potentially immunogenic T-cell peptides are shared between the A(H1N1)-2009 and "seasonal" influenza strains, it is possible that individuals with HLA types that present the remaining variable epitopes could have some T-cell immunity to the A(H1N1)-2009 pandemic strain. In this study, we ask whether exposure during successive seasonal epidemics generated at least some memory T cells that also recognize nonconserved (containing at least one amino acid variation) peptides derived from the A(H1N1)-2009 pandemic influenza virus.
Results
We probed the potential for preexisting memory T-cell responses against nonconserved A(H1N1)-2009-derived peptides. Sequence analysis of influenza viruses established that many of the A (H1N1)-2009-derived variable peptides within the main T-cell immunogenic proteins (6, 11) , nucleoprotein (NP) and matrix-1 (M1), are more like the pandemic 1918-H1N1 strain rather than the seasonal influenza strains (Table S1 ). Based on these results, we focused on the variable (although highly cross-reactive between different variants derived from seasonal influenza viruses) immunodominant NP [418] [419] [420] [421] [422] [423] [424] [425] [426] peptide that binds a large B7 allelic family (12, 13) found throughout human populations (HLA-B*3501/ HLA-B*3503/HLA-B*0702) and probed memory CD8 + T-cell specificity for 12 different NP 418 mutants derived from a spectrum of seasonal and pandemic viruses (8, (12) (13) (14) . These include the A(H1N1)-2009 virus, the 1918-H1N1 virus, and 10 seasonal viruses from 1933 to 2005 (Table 1) .
Peripheral blood mononuclear cells (PBMCs) were cultured with pooled peptides for 10 d and then restimulated with all 12 variants (either singly or together) in an IFN-γ intracellular cytokine staining assay. Despite some differences (likely related to the individual infection histories), analysis of PBMCs from healthy HLA-B*3501 ( Fig. 1 A-C, E) , HLA-B*3503 ( Fig. 1 C and  D) , and HLA-B*0702 (Fig. 1F) Fig. 1 A-F + T-cell memory, a conclusion that was further refined by stimulation in culture with the 2009-NP 418 variant alone ( Fig. 2 B and C) . In contrast, a healthy HLA-B*0702 donor had no A(H1N1)-2009-specific reactivity ( Fig. 2A) .
Two of the healthy HLA-B*3501 + donors showed low-level reactivity to the A(H1N1)-2009-NP 418 variant following culture with the NP 418 peptide pool ( Fig. 1 A and B) ; thus, the protocol was repeated using the individual NP 418 variants (Fig. 3) . These cultures were split on day 10 and restimulated separately with pooled or single peptides. The analysis confirmed that at the population level, there is a high level of cross-reactive immunity for a number of the mutants that emerged between the 1950s and 2005 (Fig. 3 by a conserved aspartic acid (D) at position (P) 4 and a lysine (K) at P5 (Fig. 1 A-F Given that point mutations within NP 418 may influence the stability of immunogenic peptide-MHC-I (pMHC-I) complexes, and thus TCR recognition (16) , profiles of pMHC-I thermal stability were then analyzed for six NP 418 variants from seasonal (1934, 1947, 1972, and 1980 ) and pandemic (1918 and 2009) viruses. All the NP 418 variants appeared equally effective at stabilizing HLA-B*3501, with the pMHC-I complexes showing (Table 1 ) comparable levels of thermostability (∼74°C; range: 73.3°C ± 0.7-75.3°C ± 1.7). Overall, the stability of the HLA-B*3501-NP 418 complexes was extremely high, an effect that can lead to prolonged half-life on the cell surface and, in turn, increase the immune-mediated selective pressure favoring the emergence of NP 418 variants.
To gain further insight into the nature of these pMHC-I epitopes, we determined the high-resolution structures (Fig. 4 and Table S3 ) of HLA-B*3501 complexed to six NP 418 peptides (from NP 418 variants emerging between 1918 and 2009). The six NP 418 peptides adopt a similar conformation in the HLA-B*3501 binding cleft, with an average rmsd of 0.13 Å 2 on the peptide when compared with the 1980-NP 418 structure (as a reference). In addition, subtle changes in MHC-I residues were observed in the specific NP 418 variants (Fig. S1 ). The NP 418 peptides use P2-P and P9-M as anchor residues buried inside the cleft. There was no secondary anchor residue in any of the HLA-B*3501-NP 418 structures. This is in contrast to other peptide-HLA-B*3501 structures solved to date, which typically use P5-D or P5-L as the secondary anchor residues (17) (18) (19) (Fig. 4) bulges out of the binding cleft, exposing its side chain to the solvent for potential contact by the TCR. The variation at this most exposed residue may, at least in part, explain the mutually exclusive crossreactivity for A(H1N1)-2009-NP 418 and 1918-NP 418 (prominent R) vs. the alternative recognition profile for the seasonal NP 418 variants (1947-NP 418 and 1972-NP 418 ) that display the DK motif (Fig. 1) . These results suggest that distinct cross-reactive CD8 + Tcell populations recognize HLA-B*3501/3503/0701 NP 418 epitopes displaying either the prominent R or DK motif.
Discussion
Overall, our study indicates how and why NP 418 changed over the decades to escape this immunodominant CD8 + T-cell response. (Table 1) . Thus, most cross-reactive immunity at the population level is directed at variants displaying the P4-D and P5-K solvent-exposed residues. The 1980-NP 418 P4-E→D mutant does not cross-react with the "DK" variants, although the P4-E substitution likely (Table S1) , it seems that our results can be generalized to at least some of the remaining 1918-H1N1-like variable T-cell peptides. (13) . The present analysis mapped the spectrum of current ex vivo CD8 + T-cell crossreactivity for NP 418 variants using human PBMCs from eight donors, including those from individuals infected with the 2009-H1N1 pandemic strain. The availability of NP 418 variants reflecting 9 decades of natural selection has further allowed the identification of two distinct cross-reactive T-cell sets (specific for ER/EK or DK) that potentially cover the possible spectrum of TCR recognition. Thus, although ∼20 different NP 418 variants are known for seasonal and pandemic influenza strains (13) , it may only be necessary to prime T-cell memory to two distinct sets of peptides with core critical motifs. In general, identification of such key solvent-exposed residues/motifs that elicit cross-reactive T-cell sets could allow the evolution of vaccination regimens that provide a measure of protection against unpredicted pandemic and seasonal influenza strains. The overall strategy might also be extended to other highly variable pathogens and to at least some cancers. ) for 2 h in the presence of 10 U/mL IL-2 in cRPMI. Diluted GolgiPlug (1:1,000; BD Biosciences) was then added and incubated for a further 5 h at 37°C. Cells were washed with PBS/1% BSA/0.02% sodium azide and stained with anti-CD8α-allophycocyanin (BD Biosciences) for 30 min on ice and then washed. Using the BD Cytofix/ Cytoperm Plus Fixation/Permeabilization Kit (BD Biosciences), cells were fixed and permeabilized and then stained with anti-IFN-γ-FITC (BD Biosciences) for 30 min on ice. Cells were analyzed by flow cytometry on a BD FACSCalibur (BD Biosciences) using FlowJo software (Tree Star, Inc., Ashland, OR). Background fluorescence of "no-peptide" controls was subtracted for the analysis.
Materials and Methods
Protein Expression, Purification, and Crystallization. Soluble class I heterodimers containing the NP peptides were prepared as described previously (21) . Crystals of the HLA-B*3501-NP 418 complexes were grown by the hanging-drop vapordiffusion method at 20°C with a protein/reservoir drop ratio of 1:1 at a concentration of 5 mg/mL in 10 mM Tris (pH 8) and 150 mM NaCl. Crystals grew using 15-25% PEG 4000, 0.2 M NH 4 acetate, and 0.1 M Na-citrate (pH 5.6).
Data Collection and Structure Determination. The peptide HLA (pHLA) crystals were soaked in a cryoprotectant solution containing mother liquor solution with a PEG concentration increased to 30% (wt/vol) and then flash-frozen in liquid nitrogen. The data were collected on the 3BM1 and 3ID1 beamlines at the Australian Synchrotron facility (Clayton, Australia) using the ADSC Quantum 210 and 315 CCD detectors (at 100 K). Data were processed using XDS software and scaled using XSCALE software (22) . The HLA-B*3501-NP 418 crystals (for all peptides) belonged to the space group P2 1 2 1 2 1 with unit cell dimensions (Table S3) , consistent with one pHLA complex in the asymmetrical unit. The structure was determined by molecular replacement using the PHASER program (23) with the HLA-B*3501-HPVG for the MHC model without the peptide (Protein Data Bank ID code 2FYY) (24) . Manual model building was conducted using Coot software (25), followed by maximum- likelihood refinement with the REFMAC 5 program (26) . "Translation, liberation, and screw-rotation" displacement refinement was also used during the refinement process to model anisotropic displacements of defined domains. The final model has been validated using the Protein Database validation Web site, and the final refinement statistics are summarized in Table S3 . All molecular graphics representations were created using PyMol (27) . 
